BMO Capital Initiates Coverage on Fate Therapeutics Inc(NASDAQ:FATE). The shares have been rated Outperform. The rating by BMO Capital was issued on Apr 12, 2016.
Fate Therapeutics Inc (FATE) shares turned negative on Fridays trading session with the shares closing down -0.04 points or -1.80% at a volume of 2,15,263. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $2.22. The peak price level was also seen at $2.22 while the days lowest was $2.1. Finally the shares closed at $2.18. The 52-week high of the shares is $8.781 while the 52-week low is $1.46. According to the latest information available, the market cap of the company is $63 M.
Fate Therapeutics Inc(FATE) last announced its earnings results on Mar 3, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $1.08M. Analysts had an estimated revenue of $580.00K. Earnings per share were $-0.26. Analysts had estimated an EPS of $-0.27.
Fate Therapeutics Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics. The Company has a number of programmed cellular therapeutic candidates in development and research. The Company’s development programs include ProHema (FT1050-modulated hematopoietic cells within umbilical cord blood (UCB)) which targets Hematologic Malignancies and Inherited Metabolic Disorders therapeutic conditions and are in Phase II Phase Ib and Phase Ib respectively. Its development programs also include Programmed hematopoietic cells within mobilized peripheral blood (mPB) (FT1050+FT4145-modulated mPB) which is for Hematologic and Malignancies therapeutic area and is in IND enablement-stage. Its research programs include Programmed Hematopoietic Cells human induced pluripotent stem cells (hiPSC)-derived Hematopoietic Cells and hiPSC-derived Myogenic Progenitor Cells.